DNA vaccines, CAR-T-cell adoptive transfer, and oncolytic virus-based approaches deplete FAP+ CAFs and restrain the tumor growth of mesothelioma, and colon, pancreatic, and lung cancers in murine models.116, 117, 118, 119 Of note, a research group generated a novel FAP immunogen that synergies with antitumor antigen vaccines in eliciting antitumor immunity, thus attenuating lung and prostate tumoral growth with increased mice survival.120. The gene discussed is FAP; the disease is lung cancer.